Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Post by TheRock07on Jul 11, 2016 10:41am

139 Views

Post# 25040820

Insider Buying

Latest 10 SEDI filings (by transaction date) for GUD within the last 6 months	?
Amended Filing

					As of 11:59pm ET July 10th, 2016
Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	Volume or Value	Price
Jun 20/16	Jun 16/16	Jakobsohn, Meir	Indirect Ownership	Common Shares	16 - Acquisition under a prospectus exemption	139,000	$8.29
Jun 20/16	Jun 16/16	Jakobsohn, Meir	Direct Ownership	Common Shares	16 - Acquisition under a prospectus exemption	111,000	$8.29
Jun 20/16	Jun 15/16	Khouri, Amal	Direct Ownership	Common Shares	30 - Acquisition under a purchase/ownership plan	425	$8.56
Jun 20/16	Jun 15/16	Kadanoff, Jeffrey Lorne	Direct Ownership	Common Shares	30 - Acquisition under a purchase/ownership plan	425	$8.56
Jun 20/16	Jun 15/16	Goodman, Jonathan	Direct Ownership	Common Shares	30 - Acquisition under a purchase/ownership plan	567	$8.56
Jun 3/16	Jun 2/16	Khouri, Amal	Direct Ownership	Common Shares	15 - Acquisition under a prospectus	12,500	$8.00
Jun 3/16	Jun 2/16	Kadanoff, Jeffrey Lorne	Direct Ownership	Common Shares	15 - Acquisition under a prospectus	12,500	$8.00
Jun 3/16	Jun 2/16	3487911 Canada Inc	Direct Ownership	Common Shares	15 - Acquisition under a prospectus	45,000	$8.00
Jun 3/16	Jun 2/16	Goodman, Jonathan	Indirect Ownership	Common Shares	15 - Acquisition under a prospectus	45,000	$8.00
Apr 4/16	Mar 30/16	Lande, Robert Nathaniel	Direct Ownership	Common Shares	30 - Acquisition under a purchase/ownership plan	1,328	$7.53
Sign up for an account at inkresearch.com to see more than 6 months of SEDI filings and to get detailed holdings information.